Clinical Trial Update: Dose Escalation Of Icotinib In Previously Treated Patients With Routine Dose [Phase 4]

View source ↗

Summary

Phase 4 dose-escalation study evaluating icotinib in previously treated non-small cell lung cancer patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• icotinib (icotinib)

Snippet

Sponsor: Betta Pharmaceuticals Co., Ltd. | Conditions: Non-small Cell Lung Cancer | Phase 4 | Status: COMPLETED